Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc.verified

KTRA

Price:

$0.1214

Market Cap:

$6.71M

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. ...[Read more]

Industry

Biotechnology

IPO Date

2013-02-22

Stock Exchange

NASDAQ

Ticker

KTRA

The PE Ratio as of April 2024 (TTM) for Kintara Therapeutics, Inc. (KTRA) is -0.02

According to Kintara Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.02. This represents a change of -95.39% compared to the average of -0.43 of the last 4 quarters.

Kintara Therapeutics, Inc. (KTRA) Historical PE Ratio (quarterly & annually)

How has KTRA PE Ratio performed in the past?

The mean historical PE Ratio of Kintara Therapeutics, Inc. over the last ten years is -1.94. The current -0.02 PE Ratio has changed 3.07% with respect to the historical average. Over the past ten years (40 quarters), KTRA's PE Ratio was at its highest in in the December 2023 quarter at -0.18. The PE Ratio was at its lowest in in the September 2016 quarter at -7.46.

Quarterly (TTM)
Annual

Average

-1.94

Median

-1.00

Minimum

-9.69

Maximum

0.00

Kintara Therapeutics, Inc. (KTRA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Kintara Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = Infinity%

Maximum Annual PE Ratio = 0.00

Minimum Annual Increase = -283444.84%

Minimum Annual PE Ratio = -9.69

Quarterly (TTM)
Annual
YearPE RatioChange
2023-0.45-25.54%
2022-0.60-60.96%
2021-1.53115.67%
2020-0.7159.81%
2019-0.44-65.22%
2018-1.28-62.53%
2017-3.41-64.79%
2016-9.69655.15%
2015-1.28-283444.84%
20130.00Infinity%

Kintara Therapeutics, Inc. (KTRA) Average PE Ratio

How has KTRA PE Ratio performed in the past?

The current PE Ratio of Kintara Therapeutics, Inc. (KTRA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-0.86

5-year avg

-0.75

10-year avg

-1.94

Kintara Therapeutics, Inc. (KTRA) PE Ratio vs. Peers

How is KTRA’s PE Ratio compared to its peers?

Kintara Therapeutics, Inc.’s PE Ratio is greater than Fresh Tracks Therapeutics, Inc. (-0.83), greater than SAB Biotherapeutics, Inc. (-0.60), greater than Theriva Biologics, Inc. (-0.39), greater than Lisata Therapeutics, Inc. (-1.13), greater than Dyadic International, Inc. (-8.03), greater than Forte Biosciences, Inc. (-0.85), greater than DiaMedica Therapeutics Inc. (-4.68), greater than Kineta, Inc. (-0.39), greater than Longboard Pharmaceuticals, Inc. (-7.74), greater than Lumos Pharma, Inc. (-0.63), less than ImmunoCellular Therapeutics, Ltd. (0), greater than Cellectar Biosciences, Inc. (-1.49), greater than Bolt Biotherapeutics, Inc. (-0.62), greater than First Wave BioPharma, Inc. (-0.26), greater than Salarius Pharmaceuticals, Inc. (-0.16), greater than Vaccinex, Inc. (-0.21), greater than GeoVax Labs, Inc. (-0.11), greater than scPharmaceuticals Inc. (-3.13), greater than Milestone Pharmaceuticals Inc. (-0.93), greater than Oncolytics Biotech Inc. (-3.92), greater than Seres Therapeutics, Inc. (-0.63), greater than aTyr Pharma, Inc. (-1.91),

Build a custom stock screener for Kintara Therapeutics, Inc. (KTRA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kintara Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kintara Therapeutics, Inc. (KTRA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kintara Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Kintara Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Kintara Therapeutics, Inc. (KTRA)?

What is the highest PE Ratio for Kintara Therapeutics, Inc. (KTRA)?

What is the 3-year average PE Ratio for Kintara Therapeutics, Inc. (KTRA)?

What is the 5-year average PE Ratio for Kintara Therapeutics, Inc. (KTRA)?

How does the current PE Ratio for Kintara Therapeutics, Inc. (KTRA) compare to its historical average?